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Until 1990, erythropoietin (EPO) was considered to have a single biological purpose and
action, the stimulation of red blood cell growth and differentiation. Slowly, scientific and
medical opinion evolved, beginning with the discovery of an effect on endothelial cell
growth in vitro and the identification of EPO receptors (EPORs) on neuronal cells. We
now know that EPO is a pleiotropic growth factor that exhibits an anti-apoptotic action on
numerous cells and tissues, including malignant ones. In this article, we present a short
discussion of EPO, receptors involved in EPO signal transduction, and their action on non-
hematopoietic cells. This is followed by a more detailed presentation of both pre-clinical
and clinical data that demonstrate EPO’s action on cancer cells, as well as tumor angio-
genesis and lymphangiogenesis. Clinical trials with reported adverse effects of chronic
erythropoiesis-stimulating agents (ESAs) treatment as well as clinical studies exploring
the prognostic significance of EPO and EPOR expression in cancer patients are reviewed.
Finally, we address the use of EPO and other ESAs in cancer patients.
Keywords: erythropoietin, erythropoietin receptor, receptor partners, cancer, cell response, angiogenesis, clinical
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INTRODUCTION
The presence of a circulating hemopoietic factor controlling the
red blood cell (RBC) production was first suggested in 1906 (1).
This humoral factor was experimentally confirmed almost half
a decade later and the name erythropoietin was given (2). In
1977, the protein was isolated from human urine (3) enabling
research toward cloning of the gene, its characterization, and
in vitro expression (4, 5). Only 4 years later, the US Food and
Drug Administration (FDA) approved the first commercially
available recombinant human erythropoietin (rHuEPO), epoetin
alfa, for the treatment of anemia associated with chronic kid-
ney disease (CKD) (6). Later on, it was approved also for use
in patients with other anemias including cancer patients under-
going chemotherapy (7). Thereafter, rHuEPO became a leading
drug for treatment of anemia virtually abolishing the need for
RBC transfusion in some types of anemia. As a result, since
the 1990s, several new erythropoiesis-stimulating agents (ESA)
have become available on the market or are under development
[reviewed in Ref. (8)].
Erythropoietin (EPO) was first considered to have a single
biological purpose and action – the stimulation of RBC growth
and differentiation and, as such safe, for use in cancer patients.
Slowly, scientific and medical opinion evolved, beginning with
the discovery of an effect on endothelial cell growth in vitro (9)
and the identification of EPO receptors (EPORs) on neuronal
cells (10). We now know that EPO is a pleiotropic growth fac-
tor that exhibits an anti-apoptotic action on numerous cells and
tissues, including malignant ones [reviewed in Ref. (11–13)]. In
this article, we present a short discussion of EPO, its signaling,
and its action on non-hematopoietic cells. This is followed by a
more detailed presentation of both pre-clinical and clinical data
that demonstrate EPO’s diverse actions on cancer cells as well
as possible receptors involved in the response of cancer cells to
EPO/ESA therapy. Finally, we review current recommendations
for the use of rHuEPO and other ESAs as supportive therapy in
cancer patients with anemia that often develops during the radio-
or chemotherapy.
ERYTHROPOIETIN
The human EPO gene spans over 3 kb and contains five exons
encoding a 193 amino acid protein (4, 5). It is a single copy
gene located on chromosome 7 at position 7q22 (14, 15). A
single splice variant of EPO gene is known (http://www.ncbi.
nlm.nih.gov/gene/2056). Gene expression is regulated by oxygen
levels through hypoxia. Transcription factors involved are stim-
ulatory HIF-2, HNF-4alpha and inhibitory GATA-2, NF-kappaB
[reviewed in Ref. (16, 17)].
During post-translation modification, the N-terminal 27
amino acid signal peptide is cleaved and R166 removed result-
ing in a 165 amino acid mature protein (18). Urinary protein
containing 166 amino acids has also been characterized (19).
The single-chain protein is heavily glycosylated with a molecu-
lar weight ranging from 30 to 39 kDa. Three N-linked (N24, N38,
and N83) and one O-linked (S126) oligosaccharide side chains
represent 35–40% of the EPO molecular mass. Protein structure is
stabilized with two intra-chain disulfide bridges between C7–C161
and C29–C33 (19, 20). N glycosylation does not affect hormone
function in vitro but is essential for in vivo biological activity like
biosynthesis, structural stability, secretion, plasma half-life, and
clearance (21–23).
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In adult human beings, the hormone is produced mainly by the
renal cortex (24, 25), while in the developing fetus, the liver is the
principal source (26). EPO is secreted into the bloodstream, circu-
lates to the bone marrow, and binds to EPOR situated on the cell
surface of erythroid progenitors promoting their survival, prolifer-
ation, and differentiation (27). EPO is also produced by numerous
non-hematopoietic cells and may act in endocrine, autocrine, and
paracrine manner (28).
Commercially available rHuEPO has the same 165 amino acid
sequence as naturally occurring hormone (29). However, the level
of glycosylation in rHuEPO depends on the expression system used
(30). Glycosylation pattern can be analyzed by isoelectric focus-
ing enabling, thus distinguishing endogenous EPO (eEPO) from
rHuEPO (31). Also, urinary and serum EPO have some minor
heterogeneity in glycosylation levels (32).
ERYTHROPOIETIN SIGNAL TRANSDUCTION
In classical signal transduction in erythropoiesis, one EPO mole-
cule binds to an EPOR homo-dimer leading to activation of the
EPO-EPOR signaling cascade. EPO has two non-identical binding
sites toward EPOR receptors, a high-affinity G151 (nano-molar)
to the first, and a low-affinity R103 (micro-molar) interaction
to the second receptor (33). Main signaling pathways activated
by EPO are JAK2/STAT5 pathway, phosphatidylinositol 3-kinase
(PI3K) pathway, RAS/MAP kinase pathway, and protein kinase C
(PKC) pathway (34) (Figure 1). The JAK2/STAT5 and RAS/MAP
kinase (RAS-RAF-MEK-ERK) pathways are associated with hor-
mone mitogenic action, while the PI3K pathway (PI3K-AKT) is
related with anti-apoptotic activities (27).
In non-hematopoietic tissue, some other receptor partners have
been proposed, including the beta common receptor (βcR) (35)
and the epinephrine B4 receptor (EPHB4) (36). The EPO mole-
cule was indicated to bind to the hetero-dimmer EPOR-EPHB4
or hetero-trimmer EPOR-βcR-EPOR. Most probably, the high-
affinity site is involved in binding to EPOR, while other receptor
partners are bound with low affinity or an alternative site result-
ing in activation of different, tissue-protective part of EPO-EPOR
signaling cascade.
FIGURE 1 | Erythropoietin receptor and signaling pathways. The structure of the receptor dimer is outlined; docking sites for several intracellular proteins
are marked with P and linked with black-dotted arrow to individual pathway components. Positive interactions are presented with full black arrows, negative
with dotted red.
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Erythropoietin receptor
The human EPOR gene spans over 6 kb and contains 8 exons
encoding a 508 amino acid protein (37). The gene is located
on chromosome 19 at position 19p13.3-p13.2 (38, 39). Sev-
eral EPOR splice variants are known such as non-coding RNA,
functional transmembrane protein (EPOR-F), truncated protein
(EPOR-T), and at least one soluble variant (EPOR-S) (40–42)
(http://www.ncbi.nlm.nih.gov/gene/2057).
EPO receptor is a member of the type I cytokine receptor super-
family (43). During post-translation modification, the N-terminal
24-amino acid signal peptide is cleaved and the protein is modified
by glycosylation, phosphorylation, and ubiquitination to a mature
66–105 kDa protein (38, 44, 45). Mature human receptor consists
of extracellular, single transmembrane, and cytoplasmic regions
(46) (Figure 1).
The majority of the EPOR is located on the cell surface of
erythroid progenitors, erythroid burst-forming units (BFU-E),
and erythroid colony-forming units (CFU-E) in the bone mar-
row. However, the EPOR is expressed by various other tissues
such as brain, heart, liver, and others where it is involved in
the tissue protection. As EPOR is present in various cancer cells,
the use of rHuEPO in cancer patients may be problematic due
to potential activation of EPO-EPOR signaling pathways result-
ing in tumor protection (anti-apoptotic action) or proliferation
(mitogenic action).
Beta common receptor (βcR)
The human colony-stimulating factor 2 receptor, beta (CSF2RB)
gene contains 14 exons and is located on chromosome 22 at posi-
tion 22q13.1 (http://www.ncbi.nlm.nih.gov/gene/1439). CSF2RB
gene encodes β-common receptor (βcR), a common beta chain
subunit of the high-affinity receptor for interleukin 3 (IL3),
interleukin 5 (IL5), and CSF2 (granulocyte-macrophage colony-
stimulating factor).
The interaction of EPOR with the βcR was discovered and
tissue protection may be signaling through a heteroreceptor
complex involving EPOR and βcR (35). This signaling net-
work is still not understood but may involve signal pathways
different from those triggered by EPOR-EPOR (47–50). The
tissue-protective effects of EPO could be mediated by an EPOR
heteroreceptor dimer EPOR-βcR or trimmer EPOR-βcR-EPOR
(Figure 2).
Ephrin type-B receptor 4 (EPHB4)
The human Ephrin receptor B4 (EPHB4) gene contains 17 exons
and is located on chromosome 7 at position 7q22 (http://www.
ncbi.nlm.nih.gov/gene/2050). Ephrin receptors were named Eph
after the EPO-producing hepatocellular carcinoma cell line from
which its cDNA was isolated. They form the largest family of
receptor tyrosine kinase (RTK) family. About 16 ephrin receptor
genes (EphA1-10, EphB1-6) have been identified in the vertebrate
genome (51), 14 of which are present in human beings. Ephrin
receptors and their ligands, the ephrins, mediate numerus devel-
opmental processes. The protein encoded by EPHB4 gene binds
to ephrin-B2 ligand and plays an essential role in vascular devel-
opment. EPHB4 was indicated also as survival factor in several
cancers (52, 53).
European patent application [EP 2 492 355 A1 (36)] dis-
closes a molecular composition(s) of a novel tissue-protective
EPO-binding receptor protein complex, termed NEPOR. NEPOR
represents a novel EPOR derived from a unique combination of
EPOR heteroreceptor dimer EPOR-EPHB4, homoreceptor EPOR-
EPOR, and EPHB4-EPHB4, and other components derived from
ephrin biology (Figure 3).
Other partners
Interaction of EPOR with several receptors has been indicated.
Some interactions were suggested only on the level of receptor
FIGURE 2 | EPOR-βcR receptor complex. Proposed structures of
tissue-protective complexes are presented: heterotrimer including βcR
homodimer with EPOR and heterodimer βcR with EPOR. Adapted from
Brines and Cerami (47).
FIGURE 3 | EPOR-tissue-protective erythropoietin receptor (nepor
receptor complex). Proposed structure of EPO interacting complexes are
presented: homodimer EPHB4, homodimer EPOR, and heterodimer
EPHB4 with EPOR. Adapted from Jackson (36).
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expression correlation (54, 55), others on adverse tumor response
to receptor-specific therapy (56, 57). The exact mechanisms of
these correlations is not known yet but are being intensively
studied.
Increased EPOR expression was related to a reduced response to
tamoxifen treatment, an estrogen receptor (ER) specific inhibitor
(56). Furthermore, EPOR receptor was shown to enhance ER
activity and promote cell proliferation (58). Several correlations
between EPOR, ER, and other steroid receptors expression have
been described (54, 55, 59, 60).
The antagonistic effect of EPOR and human epidermal growth
factor receptor-2 (HER2) co-expression on transtuzumab ther-
apy, a HER2 inhibiting antibody has also been observed (57). The
JAK2-mediated activation of SRC and inactivation of PTEN have
been proposed as underlying mechanisms.
ACTION OF EPO ON NON-HEMATOPOIETIC CELLS
EPO and its receptor have been identified in several non-
hematopoietic cells and tissue types like central nervous system,
heart, kidney, gastrointestinal system, reproductive tract, endothe-
lium, and others [reviewed in Ref. (11, 12, 61)]. In these tissues,
EPO was shown to be tissue protective in an anti-apoptotic and/or
mitogenic manner. Several ongoing pre-clinical and clinical trials
are exploring the potential use of rHuEPO and other ESAs, such
as tissue-protective agents in the brain, heart, and wound healing
[reviewed in Ref. (62, 63)].
Furthermore, EPORs have been found also on several types of
tumors and malignant cells [reviewed in Ref. (64–67)] question-
ing the use of recombinant EPO in cancer patients (68). We will
now focus on a review of various effects of EPO and its receptor on
cancer cells, being an update of EPO research reviewed by Szenajch
et al. (13).
EPO AND CANCER CELLS RESPONSE
The presence of functional EPOR was demonstrated in cancer
stem cells (69–71). Different types of tumors as well as cell lines
have been found to express EPOR mRNA transcripts, which might
be translated into full-length EPOR as well as soluble or other
truncated forms (40). In this regard, Um et al. (72) measured inter-
nalized 125I-EPO and found that just 50 high-affinity cell surface
EPO binding sites were sufficient for EPO-mediated activation of
intracellular signal transduction in SH-SY5Y and PC-12 cancer
cells. EPOR expression has been demonstrated by flow cytometry
using a specific EPOR antibody in a panel of 29 tumor cell lines,
including 18 adherent cell lines (73).
Despite the fact that many tumor cells were confirmed to pos-
sess the EPOR, there is still some debate on stimulatory effects of
EPO on these cells. On the one hand, there are papers pointing
to the proliferative response of cancer cells after rHuEPO treat-
ment (55, 74–82); on the other hand, some tumor cells, in spite of
evidence of EPOR functionality (67, 81), did not exhibit a growth
response (67, 83–86). Our previous studies revealed a weak surface
EPOR signal in A2780 cells with most of EPOR found in the cyto-
plasm, more abundantly as an intracellular membrane-associated
protein than a soluble one. Silencing EPOR expression resulted
in reduced A2780 proliferation as well as a reduction in EPO-
induced phosphorylation of ERK1/2 (81). Unlike hematopoietic
cells, where EPO-EPOR signaling is associated with increased cell
proliferation and/or survival, in tumor cells, the EPO-EPOR axis
does not always lead to increased proliferation but might increase
the resistance of cancer cells to different therapies. For more infor-
mation about the role of EPO and its receptor in growth, survival,
and therapeutic response of human cancer cells, see the critical
review of Szenajch et al. (13), where all information based on
published EPO papers through 2010 is well summarized.
Recently, the presence of EPOR signaling and EPO-induced
cellular proliferation was confirmed in renal cancer cells (80, 82),
head and neck squamous cell carcinomas (77), and cervical cancer
cell lines (78), as well as glioma cells (87).
Erythropoietin-induced proliferation of cancer cells was associ-
ated with the activation of JAK2, JAK3, STAT3, and STAT5 but not
JAK1 or STAT1 (78), AKT phosphorylation (77), ERK phospho-
rylation (87) with hTERT gene transcription by JAK2/STAT5/c-
MYC, and hTERT protein phosphorylation by PI3K/AKT (88).
Furthermore, the EPO-EPOR pathway stimulated the expression
of cyclin D1 and inhibiting the expression of p21cip1 and p27kip1
through the phosphorylation of JAK2 and ERK1/2, led to a more
rapid progression through renal cancer cell cycle (82). Interest-
ingly, EPO or stem cell factor (SCF) alone produced a modest
number of cervical cancer cell colonies, whereas the combination
EPO/SCF induced a significantly more. Similarly, co-stimulation
with EPO/SCF induced a significantly higher number of migrat-
ing cervical cancer cells than either cytokine alone. Concurrently,
EPO induced a modest, transient activation of ERK1/2, whereas
SCF and EPO/SCF prompted a strong, sustained phosphorylation
of ERK1/2 (89).
Erythropoietin was also involved in cell growth, invasion, sur-
vival, and sensitivity to the multikinase inhibitor sunitinib and
cisplatin in renal cancer cells (80) and in head and neck squamous
cell carcinoma (77), respectively. In vitro, EPO had a protec-
tive effect on radiation-treated MDA-MB-435 cells; however, EPO
treatment alone or combined with chemotherapy or hypoxia did
not influence cell survival. In vivo, EPO increased lung metas-
tases in immunocompromised mice injected with MDA-MB-231
or MDA-MB-435 cells and treated with chemotherapy relative to
mice treated with chemotherapy alone (90).
Very recently, Trošt et al. (55) confirmed the results of Arca-
soy et al. (91) with positive response of breast cancer cells to EPO.
Moreover, they demonstrated time- and concentration-dependent
manner of EPO-induced MCF-7 proliferation and EGR1, FOS,
and EPOR as transcription targets of the EPO-EPOR signal-
ing loop (55). In this regard, Inbar et al. (92) discovered that
EPO-driven EGR1 and c-FOS gene expression, as well as his-
tone H4 acetylation in breast cancer cells were mediated via
polyADP-ribosylation. EPO-induced breast cancer cell migration
was blocked by the PARP inhibitor Veliparib (ABT-888), suggest-
ing an essential role for polyADP-ribosylation in this process and
suggesting a new cancer-associated anemia treatment modality
with combined administration of EPO and PARP inhibitors (92).
Recent research revealed that EPO/EPOR contributes to the
mechanism of trastuzumab resistance in breast cancer cell line
SKBR3, and EPOR downregulation can reverse the resistance
to trastuzumab. EPOR expression may be involved in tumor
progression and proliferation in HER2-positive breast cancer
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(93). Indeed, EPO antagonized trastuzumab-induced therapeutic
effects through JAK2-mediated activation of SRC and inactiva-
tion of PTEN protein, so combined therapy of HER2-positive
cancer cells with EPO and trastuzumab reduced the response
of these cells to trastuzumab both in vitro and in vivo. Further-
more, concurrent administration of EPO and trastuzumab corre-
lated with shorter progression-free and overall survival in patients
with HER2-positive metastatic breast cancer (57). The mecha-
nism of EPO-EPOR and HER2 co-regulation in breast cancer
was confirmed by miR-125b, which is downregulated in metasta-
tic breast cancers and a significant positive correlation between
EPOR and HER2 levels that are both targets of miR-125b was
demonstrated (94).
Because of adverse tumor response and/or poorer survival in
ESA-treated cancer patients, studies of EPO effects on cancer stem
cells was initiated. Cao et al. (69) found that glioma stem cells
(GSC) express higher levels of EPOR than matched non-stem
glioma cells. They targeted EPOR expression in GSG with shRNA
and reduced growth, survival, and neurosphere formation capac-
ity, so confirmed the role for EPOR in GSC maintenance. A small
molecule inhibitor of STAT3 led to reduced GSG growth and sur-
vival. EPO-EPOR signaling was also critical for survival in vivo, as
targeting EPOR expression decreased GSC tumorigenic potential
(69). Furthermore, Todaro et al. (71) showed that breast cancer
stem-like cells (BCSC) isolated from patient tumors express the
EPOR and respond to EPO treatment with increased proliferation
and self-renewal. Importantly, EPO stimulation increased BCSC
survival and resistance to chemotherapeutic agents, probably by
EPO-activated AKT and ERK pathways and promoted metasta-
tic progression of tumor xenografts in the presence and in the
absence of chemotherapy treatment. These results suggest that
EPO acts directly on BCSC by activating specific survival pathways,
resulting in BCSC protection from chemotherapy and enhanced
tumor progression (71). Moreover, EPO/EPOR promoted tumori-
genesis in genetically engineered mouse models of breast cancer
by activating JAK/STAT signaling in breast tumor-initiating cells
(TICs) and promoted its self-renewal. EPO gene expression cor-
related with shortened relapse-free survival and pharmacologic
JAK2 inhibition revealed a synergistic effect with chemotherapy in
tumor growth inhibition in vivo (70).
EPO AND TUMOR ANGIOGENESIS AND LYMPHANGIOGENESIS
In 1990, Anagnostou et al. (9) found that EPO enhances the pro-
liferation and migration of human umbilical vein endothelial cells
and bovine adrenal capillary endothelial cells (95, 96) and demon-
strated the presence of EPOR mRNA in human umbilical vein
endothelial cells, as well as strong positive EPOR protein staining
of the vascular endothelium in vivo (97). The presence of EPOR
was also shown by Yamaji et al. (98), who suggested that brain cap-
illary endothelial cells express not only an authentic form of EPOR
(EPOR-F) but also a soluble one (EPOR-S) and that EPO acts
directly on brain capillary endothelial cells as a competence factor.
EPO signaling as a mitogen of endothelial cells was conducted via
tyrosine phosphorylation of proteins including phosphorylation
of transcription factor STAT-5, which is similar to that occur-
ring in erythroid cells (99). Moreover, experiments performed in
cultured vascular cells demonstrated that EPO robustly induced
phosphorylation of STAT-5 in HUVEC cells, but only very weakly
in smooth muscle cells (100). Results of our group revealed that
conditioned media of EPO treated A2780 cells under hypoxic con-
ditions induced significant STAT-5 phosphorylation, as well as
proliferation of HUVEC cells. A new finding is the fact that pro-
stimulatory effect of hypoxic A2780 media was partly mediated
by EPO. Furthermore, EPO increased secretion of IL-4, IL-5, IL-6,
IL-8, IL-10, IL-12, IL-13, GM-CSF, and IFN γ by A2780 cells in
hypoxic conditions (101).
An in vivo angiogenic potential of EPO was originally demon-
strated by Yasuda et al. (102) who found that injection of EPO
into the ovariectomized mouse uterine cavity promoted blood
vessel formation of the endometrium. Similarly, Ribatti et al.
(103) demonstrated that EPO induced a potent in vivo angio-
genic response of the chick embryo chorioallantoic membrane.
Furthermore, the role of EPO in physiological angiogenesis was
described during wound healing and in the developing of mouse
embryo (104, 105).
The study of Yasuda et al. (106) revealed that normal human
cervix and endometrium, as well as ovary malignant tumors of
female reproductive organs produce EPO and EPOR, and that
the tumor cells themselves and capillary endothelial cells are sites
responsive to the EPO signal. Yasuda et al. (107) proposed the
presence of a paracrine or autocrine EPO-EPOR loop and its con-
tribution to tumorigenesis in female reproductive organs based
on the mitogenic action of EPO as well as on the finding that
injection of soluble EPOR (EPOR-S) or EPO-monoclonal anti-
body into blocks of tumor specimens was followed by apoptosis
of tumor cells and endothelial cells. Although some studies have
not confirmed a direct stimulatory effect of EPO on tumor cells,
there is ample evidence of this effect on endothelial cell prolif-
eration and/or angiogenesis of tumors. In this regard, EPO xin-
duced angiogenesis in chemically induced murine hepatic tumors
(108) and accelerated the growth of EPOR negative Lewis lung
carcinoma cells by promoting tumor angiogenesis in vivo (109).
Interestingly, an EPO analog stimulated neovascularization
in colorectal liver metastases of hepatectomized and non-
hepatectomized mice (110). Moreover, Nico et al. (111) demon-
strated that EPO secreted by glioma tumor cells affected glioma
vascular endothelial cells and promoted angiogenesis in a
paracrine manner. Specificity of the EPO effect was shown through
an anti-EPO antibody, which was able to significantly inhibit the
angiogenesis response. Despite the absence of melanoma growth
stimulation in vivo, EPO increased vascular size in the xenografts.
Indeed, EPO-induced angiogenesis in Matrigel plug assays, and
neutralization of EPO secreted by melanoma cells resulted in
decreased angiogenesis, which supports the role of EPO/EPOR in
melanoma progression via angiogenesis stimulation (112). Even
more interestingly, EPO accelerated the tumor growth of MMQ
pituitary adenoma xenografts lacking EPOR via enhancement of
angiogenesis in vivo, without a direct EPO effect on MMQ cells
in vitro. EPO administration increased phosphorylation of JAK2,
STAT3, and VEGF expression in HUVEC cells in vitro and in
MMQ cell xenografts in vivo (113). The authors suggest that EPO
administration may promote the growth of pituitary adenomas by
enhancing angiogenesis through EPO-JAK2-STAT3-VEGF signal-
ing pathway and should be used with caution in anemia patients
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Table 1 | Clinical trials with reported effects of ESA in cancer patients performed between 2009 and 2014.
Study (reference) Type No. of patients
(cancer type)
Therapy Support
therapy
Hb control Disease control Observations
Mäenpää et al. (138) N =114 (various) EB ↑HRQoL
Thomaidis et al. (139) Ph2 N =118 (esophagogastric) Cx EB ↑Hb (ESA) ↑OS, RFS (ESA)
AGO-ETC Moebus et al.
(123)
N =1.284 (breast) Cx EA ↑Hb, ↓TF (ESA) ↔OS, RFS ↑TE (ESA)
GINECO Weber et al.
(140)
Ph2 N =100 (ovarian) Cx EA ↓NT
Ohashi et al. (141) Meta N =511 (CIA, various) Cx DP, EB ↓TF (ESA) ↔OS, RFS ↔TE
Michallet et al. (142) N =107 (leukemia) Cx, T ESA ↑Hb, ↓TF (ESA) ↔OS, RFS ↑HRQoL (ESA), ↔TE
Tonia et al. (124) Meta N =20.102, 91 trials ESA ↓TF (ESA) ↑TE, HRQoL (ESA)
Stehman et al. (143) N =1.864 (ovarian) Cx G-CSF, ESA ↔OS multivariate analysis
CHOICE Aerts et al.
(144); Van Belle et al.
(145, 146)
N =1.887 (various) Cx DP ↑Hb (ESA) Five severe drug
reactions
Kerkhofs et al. (147) N =113 Cx EA ↑Hb (ESA) NR
Canon et al. (125) Ph3 N =705 Cx DP ↑Hb (ESA) ↑TE (ESA)
Bustos et al. (126) N =685 (CIA, various) Cx DP ↑Hb (ESA) ↑TE (ESA)
Cabanillas et al. (148) N=109 (leukemia,
lymphoma)
Cx EA ↓TF (ESA) ↔CR ↔HRQoL
Cantrell et al. (149) N =343 (CIA, ovarian) Cx ESA ↔OS, PFS
Fujisaka et al. (127) Ph3 N =186 (CIA, various) Cx EB ↑Hb (ESA) ↔OS ↑HRQoL, ↑TE (ESA)
NOGGO-AGO Blohmer
et al. (150)
Ph3 N =257 (cervical) Cx, Rx EA ↑Hb (ESA) ↑RFS (ESA), ↔OS ↔TE
PREPARE Untch et al.
(128, 129)
Ph3 N =733 (breast) Cx, Na DP ↑Hb (ESA) ↓RFS (ESA) ↑TE (ESA)
Nagel et al. (151) Ph2 N =74 (SCLC) Cx DP ↓TF (ESA) ↔PFS
RETRA Eisterer et al.
(152)
N =309 (various) Cx DP ↓TF (ESA)
Djavan et al. (153) N =1.567 (prostate) S ESA ↔RFS
Villegas et al. (130) Ph2 N =44 (MDS) DP ↑TE (ESA)
Rørth et al. (154) N=16 (solid) Cx DP ↑Hb (ESA) ↑HRQoL (ESA)
Tjulandin et al. (155) N =186 (CIA, various) Cx ET ↑Hb, ↓TF (ESA) ↔AE
Esquerdo et al. (156) N =100 (CIA, solid) Cx DP ↑Hb, ↓TF (ESA)
Chavez-MacGregor
et al. (131)
Retro N =2.266 (breast) Cx ESA ↑TE (ESA)
Gómez et al. (157) (gastrointestinal) Cx EB ↑Hb (ESA) NR
Gomez-Alamillo et al.
(158)
N =22 (solid) Rx, Na EB ↑Hb (ESA)
(Continued)
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Table 1 | Continued
Study (reference) Type No. of patients
(cancer type)
Therapy Support
therapy
Hb control Disease control Observations
Schwartzberg et al.
(159)
Ph2 N =752 (CIA, various) Cx DP ↑Hb (ESA) ↔AE
Ray-Coquard et al. (160) N =2.912 (solid) Cx DP ↑Hb (ESA)
Pronzato et al. (161) N =223 (breast) Cx EA ↑Hb (ESA) ↔OS, TR, AE ↑PRO, HRQoL (ESA)
Vargas et al. (162) Ph4 N =157 (CIA, various) Cx, Rx EA ↑Hb, ↓TF (ESA) ↑AE (ESA)
Auerbach et al. (163) Ph2 N =242 (solid) Cx, DP, Fe ↑Hb (Fe) ↔AE
Maccio et al. (164) N =148 (various) Cx EB, Fe ↔Hb (Fe)
Ichinose et al. (165) Ph2 N =132 (lung, ovarian) Cx DP ↑Hb (ESA) ↑HRQoL (ESA)
GHSG HD15EPO
Engert et al. (166)
N =1.379 (HL) Cx EA ↓TF (ESA) ↔OS, RFS, PFS, ↔TE
Gascon et al. (135) Ph2 N =153 (NSCLC) Cx CERA, DP ↔Hb ↓OS (ESA) Terminated early
Muravyov et al. (167) N =40 (solid) Cx EB ↑Hb (ESA)
Stull et al. (168) N =1.494 (various) Cx DP ↑Hb (ESA) ↑HRQoL (ESA)
Tjulandin et al. (169) N =223 (CIA, various) Cx ET, EA ↑Hb (ESA)
Roddy et al. (132) N =79 (colorectal) Cx ESA ↑TE (ESA)
Hoskin et al. (170) N =301 (head and neck) Rx EA ↑Hb (ESA) ↔OS, RFS ↔AE
Vansteenkiste et al.
(171)
Ph3 N =705 (CIA, solid) Cx DP ↑Hb, ↓TF (ESA)
Grobmyer et al. (172) N =40 (abdominal) S EA ↔TF
BRAVE Aapro et al.
(133)
N =463 (breast) Cx EB, At ↑TE (ESA), ↓TE (ESA,
At)
Aapro et al. (134) Meta N =2.297 (breast) Cx EB ↔OS ↑TE (ESA),
Hernandez et al. (173) Ph3 N =386 (CIA, solid) Cx DP ↓TF (ESA) ↔HRQoL, TE,
Greenberg et al. (174) Ph3 N =110 (MDS) Cx ESA, GCSF ↔OS ↑HRQoL (ESA)
Repetto and CIPOMO
Investigators (175)
N =1.175 (various) Cx ESA, GCSF
Bohlius et al. (136) Meta N =13.933 (various) ESA ↓OS (over ↑Hb)
Lambin et al. (137) N =1.397 (head and neck) Cx, Rx ESA ↓OS (over ↑Hb)
Tzekova et al. (176) Ph3 N =216 (solid) Cx EZ ↑Hb (ESA) ↓TE (EZ), ↑HRQoL
(ESA)
Study type: Meta, meta-analysis; Ph2-4, clinical study phase 2–4; Retro, retro-analysis. Disease/cancer type: CIA, chemotherapy-induced anemia; HL, Hodgkin’s
lymphoma; MDS, myelodysplastic syndrome; NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer. Therapy: At, antithrombotic; CERA, continuous ery-
thropoietin receptor activator; Cx, chemotherapy; DP, darbepoetin; EA, epoetin alpha; EB, epoetin beta; ESA, erythropoiesis-stimulating agent; ET, epoetin theta;
EZ, epoetin zeta; Fe, iron supplementation; Na, neoadjuvant; Rx, radiotherapy; S, surgery; TF, transfusion; T, transplantation. Disease control and observations: AF,
adverse effects; CR, complete remission; DFS, disease-free survival; Hb, hemoglobin; HRQoL, health-related quality of life; NR, not reported; NT, neurotoxicity;
OS, overall survival; PFS, progression-free survival; PRO, patient-reported outcomes; RFS, relapse-free survival; TE, thrombotic events; TR, tumor response; ↑/↓/↔,
increased/decreased/no significant difference.
Studies with indicated negative effects are marked in gray.
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Table 2 | Clinical studies exploring prognostic significance of EPO and EPOR expression in cancer patients.
Study (reference) No. of patients
(cancer type)
Therapy EPO expression
as PF (method)
EPOR expression
as PF (method)
Other observations
Seibold et al. (178) N =114 (head and
neck SCC)
S, Rx, IPF – no EPO: ↑LRC,
↑MFS, ↑OS
IPF – no EPOR: ↑OS
Lin et al. (180) N =256 (oral SCC) S / IPF – ↑EPOR: ↑ATB, ↓OS,
↓DSS (qPCR, WB, IHC)
Wang et al. (120) N =172 (GAC) IPF – ↓OS; ↑EPO: ↑EPOR,
↑ATB, ↑MD (IHC)
↑EPOR: ↑ATB, ↑MD (IHC) ↑VEGF-↓EPOR
Welsch et al. (177) N =104 (PDAC) IPF, ↑sEPO: ↓OS (qPCR,
ELISA, IHC)
(qPCR, IHC)
Gombos et al. (184) N =24 (colorectal AC) ↑EPO (IHC, qPCR, WB) ↑EPOR (IHC, qPCR, WB) ↑EPO and EPOR in
ischemia/necrosis
Beschorner et al. (185) N =43 (CPT) / ↓EPOR (IHC, qPCR, WB)
Rades et al. (179) N =62 (NSCLC) Rx IPF; no EPO: ↑LRC, ↑OS ↑EPO and ↑EPOR:
↓PF
Volgger et al. (181) N =107 (breast) ESA / ↑EPOR: ↑ER and ↑PR, ↑CRR,
↔OS (IHC, qPCR, WB)
Xu et al. (186) N =96 (prostate: PCa,
PIN, BPH)
↑EPO (BPH) (IHC) ↑EPOR (PCa, PIN) (IHC)
Liang et al. (57) N =55/37 (breast) TZ, ESA / ↑EPOR and ↑HER2: ↓TR to
TZ, ↓PFS, ↓OS (IHC)
Mirmoham-medsadegh
et al. (187)
N =20 (melanoma) / ↑EPOR (qPCR, IHC, WB)
Giatromanolaki et al.
(182)
N =72 (endometry) / ↑EPOR: ↑ATB, ↓PF (IHC) ↑EPOR-↑HIF1α-
↑VEGF
Larsson et al. (56) N =500 (breast:
ER+ , PR+)
TAM (qPCR, ELISA) ↑EPOR: ↓TR to TAM (qPCR,
IHC)
Li et al. (119) N =65 (tongue SCC) S IPF (IHC) IPF (IHC)
Miller et al. (73) N =159 (various) ESA (qPCR) ↔PFS, ↑EPOR: ↓PFS in
unresected T (qPCR)
JAK2, HSP70
Küster et al. (183) N =131 (meningioma) / ↓EPOR: ↑CRR (IHC, qPCR,
WB)
EPOR-F, EPOR-T,
EPOR-S
Disease/cancer type: BPH, benign prostatic hyperplasia; CPT, choroid plexus tumors (glioma, meningioma); ER+, estrogen receptor positive; GAC, gastric adenocar-
cinoma; NSCLC, non-small-cell lung cancer; PR+, progesterone receptor positive; SCC, squamous cell carcinoma; PCa, prostate carcinoma; PDAC, pancreatic ductal
adenocarcinoma; PIN, prostate intraepithelial neoplasia.Therapy: ESA, erythropoiesis-stimulating agent; Rx, radiotherapy; S, surgery;TAM, tamoxifen;TZ, trastuzumab.
Prognostic factor and observations: ATB, aggressive tumor behavior (TNM stage, T and N classification); CRR, cancer recurrence rate; DSS, disease-specific survival;
IPF, independent prognostic factor; LRC, loco-regional control; MD, microvessel density; MFS, metastases-free survival; OS, overall survival; PF, prognostic factor;
PFS, progression-free survival; sEPO, serum EPO;TR, tumor response; ↑/↓/↔, increased/decreased/no significant difference. Methods: IHC, immunohistochemistry;
qPCR, quantitative PCR; WB, Western blotting.
bearing pituitary adenoma due to its potential deleterious effects
(113). On the contrary, very recently Pascual et al. (114) found
that preoperative administration of EPO stimulates tumor recur-
rence in an animal model of colon cancer, but no evidence of
increased angiogenesis or enhanced-cell proliferation as possible
mechanisms of EPO-induced recurrence was seen. Importantly,
EPO/EPOR levels correlated well with angiogenesis and progres-
sion of patients with hepatocellular carcinoma, neuroblastoma,
squamous cell carcinoma of the tongue, melanoma, and gastric
adenocarcinoma (115–120).
The lymph node as a new target of EPO was presented by Lee
et al. (121) They showed that EPO can stimulate both lymph node
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lymphangiogenesis and nodal metastasis by increased migration,
capillary-like tube formation, and dose- and time-dependent pro-
liferation of human lymphatic endothelial cells in tumor-bearing
animals. Intraperitoneal administration of EPO induced AKT and
ERK1/2 signalization followed by peritoneal lymphangiogenesis
stimulation. Furthermore, systemic treatment of EPO increased
infiltration of CD11b(+) macrophages in tumor-draining lymph
nodes and increased VEGF-C expression in lymph node-derived
CD11b(+) macrophages, as well as in bone marrow-derived
macrophages in a dose- and time-dependent manner (121).
According to McKinney and Arcasoy (122), there are two poten-
tial mechanisms by which rHuEPO therapy may promote tumor
progression and reduce survival in some cancer patients: (1)
rHuEPO therapy may exert local effects in tumors, acting directly
on tumor cells or other cell types in the tumor microenviron-
ment, such as the vascular endothelium and tumor-associated
macrophages or (2) rHuEPO may cause systemic effects that indi-
rectly alter tumor biology in an unfavorable manner or directly
give rise to specific systemic toxicities that impair survival. In
this regard, elevated hemoglobin, increased viscosity, platelet acti-
vation, endothelial progenitor mobilization, immunomodulatory
effects, and others could play significant roles. We add a third
potential mechanism and this is direct effect of EPO on cancer stem
and/or TICs, which could explain enhanced tumor progression
and poor survival of some cancer patients treated with EPO.
EPO (ESA) AND CLINICAL STUDIES
Several clinical trials have addressed the effects of one of the
EPO/ESA treatments on disease control in cancer patients on co-
temporal anti-cancer therapy, such as chemotherapy, radiotherapy,
neoadjuvant therapy, and surgery. Such EPO/ESA treatments are
long termed and rarely single dosed. The review of clinical trials
performed between 2009 and 2014 is presented in Table 1, being an
update of review by Szenajch et al. (13). Some of the studies indi-
cate a negative outcome (marked in gray). Most of the reported
negative effects are due to increased thrombotic events, a complica-
tion driven by an increased number of RBC (123–134). However,
some of the studies also indicate a reduced recurrence free sur-
vival and overall survival (128, 129, 135–137). Negative effects on
overall survival were already shown previously by several studies,
reviewed by Szenajch et al. (13).
Clinical studies exploring the prognostic significance of EPO
and EPOR expression in cancer patients have also been explored
and are listed in Table 2. Several studies indicated increased
EPO expression as prognostic factor for reduced overall survival
(120, 177) or vice versa, no EPO expression as prognostic factor
for increased overall survival (178, 179). Furthermore, increased
EPOR expression was identified as prognostic factor for reduced
overall survival, more aggressive tumor behavior, and progression-
free survival (57, 73, 120, 180–182). Increased EPOR expression
was also linked to reduced response to anti-cancer treatment (56,
57). While no or reduced EPOR expression was identified as prog-
nostic factor for increased overall survival (178) and in contrast,
also to increased cancer recurrence rate (183). Most of these stud-
ies did not characterize the subtype of EPOR isoforms, which
is crucial for interpretation of the data, as indicated by Küster
et al. (183).
Based on discussed clinical studies, the adverse effect of
EPO/ESA in cancer patients during anti-cancer therapy could be
related to chronic EPO treatment. Such EPO/ESA treatments are
long termed and rarely single dosed. We suggest that the con-
current use of long-termed EPO/ESA and anti-cancer treatment
is the main reason for EPO/ESA negative effects on response to
anti-cancer therapy, overall survival, and disease recurrence. The
mechanisms are still not well understood and more profound mol-
ecular and biochemical characterization is needed; however, they
may be linked to one of the EPO/ESA mechanisms indicated in the
previous chapter. EPOR, βcR, and EPHB4 were previously shown
to be expressed in various tumors. We do speculate that one of
these receptors and/or possible analogs of these receptors may be
involved in the response of cancer cells to EPO/ESA therapy.
CONCLUSION
A plethora of scientific evidence demonstrates a growth-
promoting, anti-apoptotic action of EPO and other ESAs on
non-hematopoietic cells, both normal and malignant, and this
is supported by numerous clinical observations showing adverse
effects of EPO administration on the clinical management of
tumor growth and progression. As anticipated just a few years ago
(28), physicians who care for anemic cancer patients have been fac-
ing a dilemma, whether to treat the anemic patient with an ESA,
thereby potentially increasing the risk of worsening the malig-
nancy,or to withhold ESA treatment,with resultant patient fatigue,
reduced physical activity, increased hypoxic stress, and reliance on
transfusion therapy. Primary tumors are not yet EPOR typed (like
breast cancers are assessed for ER/PR expression) though this idea
should be considered. There has been much discussion of EPO use
in cancer patients, and several professional and regulatory orga-
nizations and authorities have issued various guidances. Perhaps,
the following “rule” used by several clinicians interviewed by one
of the authors should be considered. If the cancer patient is being
treated with curative intent, avoid the use of ESAs. If the treatment
plan is more conservative or palliative, consider ESAs for anemia
treatment, but proceed with great caution.
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